Regeneron Pharmaceuticals reported Thursday that first-quarter sales of Eylea in the US rose 15 percent year-over-year to $984 million, besting analyst estimates of around $922 million. The company’s overall sales increased 15 percent to $1.5 billion, in line with forecasts, as net income surged 92 percent to $478 million.
CEO Leonard Schleifer remarked “Regeneron’s commercial business continues to advance with positive sales growth for Eylea and strong underlying demand for Dupixent.” In the quarter, global sales of Eylea lifted 20 percent to $1.6 billion, while Dupixent posted revenue of $131 million, missing estimates of around $168 million.
In the 3-month period, sales of Praluent jumped 67 percent versus the same quarter of 2017 to $60 million, but fell short of analyst forecasts of $66 million. In October 2017, a US appeals court overturned a lower court ruling blocking Regeneron and partner Sanofi from selling the PCSK9 inhibitor in the US after a separate court determined that the companies infringed patents held by Amgen related to Repatha.